ES2194477T3 - Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm. - Google Patents

Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.

Info

Publication number
ES2194477T3
ES2194477T3 ES99930387T ES99930387T ES2194477T3 ES 2194477 T3 ES2194477 T3 ES 2194477T3 ES 99930387 T ES99930387 T ES 99930387T ES 99930387 T ES99930387 T ES 99930387T ES 2194477 T3 ES2194477 T3 ES 2194477T3
Authority
ES
Spain
Prior art keywords
water
size
procedure
insoluble
insoluble compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99930387T
Other languages
English (en)
Inventor
Gary W Pace
G Michael Vachon
K Awadhesh Mishra
Inge B Henriksen
Val Krukonis
Anthony Godinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skyepharma Canada Inc
Original Assignee
Skyepharma Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Canada Inc filed Critical Skyepharma Canada Inc
Application granted granted Critical
Publication of ES2194477T3 publication Critical patent/ES2194477T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/04—Specific aggregation state of one or more of the phases to be mixed
    • B01F23/043—Mixing fluids or with fluids in a supercritical state, in supercritical conditions or variable density fluids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/51—Methods thereof
    • B01F23/511—Methods thereof characterised by the composition of the liquids or solids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/56—Mixing liquids with solids by introducing solids in liquids, e.g. dispersing or dissolving
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/20—Jet mixers, i.e. mixers using high-speed fluid streams
    • B01F25/28—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector
    • B01F25/281—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector the jet injector being of the explosive rapid expansion of supercritical solutions [RESS] or fluid injection of molecular spray [FIMS] type, i.e. the liquid is jetted in an environment (gas or liquid) by nozzles, in conditions of significant pressure drop, with the possible generation of shock waves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Procedimiento para preparar una suspensión de partículas de un compuesto biológicamente activo insoluble en agua o substancialmente insoluble en agua con un tamaño de hasta 2000 nm, que comprende las etapas de: (a) disolver un compuesto biológicamente activo insoluble en agua o substancialmente insoluble en agua y un primer modificador de superficie en un gas comprimido licuado que sea disolvente para el mismo y formar una solución; y (b) expandir la solución fluida comprimida preparada en la etapa (a) en agua o en una solución o dispersión acuosa que comprende un segundo modificador de superficie y otros agentes solubles en agua opcionales, produciéndose de esta manera una suspensión de micropartículas, donde el primer y segundo modificadores de superficie son diferentes.
ES99930387T 1998-06-19 1999-06-18 Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm. Expired - Lifetime ES2194477T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8985298P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
ES2194477T3 true ES2194477T3 (es) 2003-11-16

Family

ID=22219900

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99930387T Expired - Lifetime ES2194477T3 (es) 1998-06-19 1999-06-18 Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.

Country Status (14)

Country Link
US (1) US6177103B1 (es)
EP (1) EP1089714B1 (es)
JP (2) JP4693238B2 (es)
KR (1) KR100622047B1 (es)
CN (1) CN1160059C (es)
AT (1) ATE233549T1 (es)
AU (2) AU755993C (es)
CA (1) CA2335472C (es)
DE (1) DE69905716T2 (es)
ES (1) ES2194477T3 (es)
HK (1) HK1039566A1 (es)
IL (2) IL140276A0 (es)
SE (1) SE521255C2 (es)
WO (1) WO1999065469A2 (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
WO2001024917A1 (en) * 1999-10-07 2001-04-12 Battelle Memorial Institute Method and apparatus for obtaining a suspension of particles
AU2729101A (en) * 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
AU2001247244B2 (en) 2000-02-28 2005-06-02 Genesegues, Inc. Nanocapsule encapsulation system and method
DE60119905T2 (de) * 2000-03-09 2007-01-11 Ohio State University Research Foundation, Columbus Verfahren zur Herstellung von Feststoffdispersionen
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6541542B2 (en) * 2000-09-29 2003-04-01 Eastman Chemical Company Process for production of polymeric powders
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2004534900A (ja) 2001-07-12 2004-11-18 イーストマン コダック カンパニー 圧縮流体配合物
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
CA2461349C (en) * 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003066021A2 (en) * 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2003072127A1 (en) * 2002-02-25 2003-09-04 Phasex Corporation Method for drying water-borne materials
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
FR2838356B1 (fr) * 2002-04-15 2004-05-28 Separex Sa Procede d'obtention d'une suspension stable de particules dans un liquide
EP1499296B1 (en) * 2002-04-15 2012-04-04 MAP Pharmaceuticals Inc Formulation of fine particles using liquefied or dense gases
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1531799A1 (en) * 2002-06-10 2005-05-25 Elan Pharma International Limited Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
GB0229714D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel apparatus and method
KR20060052849A (ko) * 2003-08-06 2006-05-19 에자이 가부시키가이샤 약물 초미립자의 제조 방법 및 제조 장치
US20050258288A1 (en) * 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
US7582275B1 (en) 2004-01-26 2009-09-01 The United States Of America As Represented By The Secretary Of The Air Force Method of processing filamentary nanocarbon
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
GB0406515D0 (en) * 2004-03-23 2004-04-28 Novartis Ag Organic compounds
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
HUE028288T2 (en) * 2004-03-31 2016-12-28 Toyama Chemical Co Ltd A fine dispersion of a low solubility drug and a process for producing it
US7754243B2 (en) 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US7293570B2 (en) * 2004-12-13 2007-11-13 Cool Clean Technologies, Inc. Carbon dioxide snow apparatus
ES2265262B1 (es) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
KR20140002810A (ko) * 2005-05-05 2014-01-08 사노피-아벤티스 유.에스. 엘엘씨 안정한 나노입자 제형
KR20080027340A (ko) * 2005-06-14 2008-03-26 백스터 인터내셔널 인코포레이티드 약물-약물 상호작용을 최소화하기 위한 제약학적 제형
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2007007524A (ja) * 2005-06-29 2007-01-18 Kagawa Industry Support Foundation 超臨界溶液急速冷却法による単分散超微粒子の製造方法及び装置
WO2007009986A2 (en) * 2005-07-19 2007-01-25 Activery Biotech, S.L. Process for obtaining a composite
ES2292300B1 (es) * 2005-07-19 2009-02-16 Sociedad Española De Carburos Metalicos, S.A.(Titular Al 50%) Procedimiento para la obtencion de un material compuesto.
US7608461B1 (en) * 2005-09-16 2009-10-27 Sandia Corporation Surface engineered nanoparticles for improved surface enhanced Raman scattering applications and method for preparing same
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
EP1960501B1 (en) * 2005-12-16 2012-01-25 Unilever N.V. Surface-active material and its application
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
BRPI0718390A2 (pt) * 2006-10-17 2013-11-26 Unilever Nv Composição alimentícia compreendendo bolhas de gás e processo para prepará-la.
AU2007312500B2 (en) * 2006-10-17 2011-04-07 Unilever Plc Aerated food product and process for preparing it
CA2665927A1 (en) * 2006-10-17 2008-04-24 Unilever Plc Frozen aerated food products comprising surface-active fibres
CN101528054B (zh) * 2006-10-17 2013-03-13 荷兰联合利华有限公司 包含气泡的食品组合物及其制备方法
EP2081444A1 (en) * 2006-10-17 2009-07-29 Unilever N.V. Food composition comprising gas bubbles and process for preparing it
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及***
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
JP5004333B2 (ja) * 2006-12-08 2012-08-22 日機装株式会社 ナノオーダ粒子製造装置
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
KR101860294B1 (ko) 2009-05-11 2018-07-02 베르그 엘엘씨 외대사성 변환인자, 다차원적 세포내 분자, 또는 환경 요인을 사용한 종양적 장애의 진단 방법
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
PT2544663T (pt) 2010-03-12 2018-04-05 Berg Llc Formulações intravenosas de coenzima q10 (coq10) e métodos de uso da mesma
AU2011232103B2 (en) 2010-03-22 2013-10-24 Instillo Gmbh Method and device for producing microparticles or nanoparticles
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
JP5932993B2 (ja) 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
US20140235676A1 (en) * 2011-10-13 2014-08-21 Case Western Reserve University Rxr agonist compounds and methods
CN104394850A (zh) 2012-02-16 2015-03-04 布莱特赛德创新有限公司 膳食和营养组合物及应用的方法
US9901893B2 (en) 2013-03-28 2018-02-27 Instillo Gmbh Apparatus and method for producing dispersions and solids
KR102279451B1 (ko) 2013-04-08 2021-07-19 버그 엘엘씨 코엔자임 q10 병용 요법을 이용한 암 치료
CN105705162A (zh) 2013-09-04 2016-06-22 博格有限责任公司 通过持续输注辅酶q10来治疗癌症的方法
EP3188716B1 (en) 2014-09-03 2022-10-26 GeneSegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
FI20140266A (fi) 2014-10-06 2016-04-07 Nanoform Finland Oy Menetelmä ja laite nanopartikkeleiden valmistamiseksi
CN110115952B (zh) * 2018-02-05 2021-10-15 绍兴吉能纳米科技有限公司 一种可使用低温液化气体的高压均质方法
WO2020234448A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
WO2021075003A1 (ja) * 2019-10-16 2021-04-22 株式会社 ナノ・キューブ・ジャパン 難溶性物質の超微粒子の分散液の製造方法
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998753A (en) * 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
SI9400079B (sl) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
DE69734988T2 (de) 1996-08-22 2006-09-21 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen stoffen und verfahren zu deren herstellung
US6299906B1 (en) * 1998-04-09 2001-10-09 Hoffmann-La Roche Inc. Process for making submicron particles

Also Published As

Publication number Publication date
CN1312708A (zh) 2001-09-12
US6177103B1 (en) 2001-01-23
CA2335472C (en) 2008-10-28
WO1999065469A2 (en) 1999-12-23
JP2011079839A (ja) 2011-04-21
AU755993B2 (en) 2003-01-02
AU4693899A (en) 2000-01-05
SE521255C2 (sv) 2003-10-14
CN1160059C (zh) 2004-08-04
WO1999065469A3 (en) 2000-03-02
KR100622047B1 (ko) 2006-09-07
CA2335472A1 (en) 1999-12-23
KR20010053041A (ko) 2001-06-25
EP1089714B1 (en) 2003-03-05
AU2003203459A1 (en) 2003-06-12
ATE233549T1 (de) 2003-03-15
JP4693238B2 (ja) 2011-06-01
SE0004620L (sv) 2001-02-08
EP1089714A2 (en) 2001-04-11
AU2003203459A8 (en) 2010-04-29
DE69905716D1 (de) 2003-04-10
DE69905716T2 (de) 2004-02-05
AU755993C (en) 2003-10-30
JP2002518318A (ja) 2002-06-25
HK1039566A1 (zh) 2002-05-03
IL140276A (en) 2007-07-24
SE0004620D0 (sv) 2000-12-14
IL140276A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
ES2194477T3 (es) Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.
AR030245A1 (es) Composiciones de gel que contienen metronidazol
JP2002518318A5 (es)
ATE386506T1 (de) Verabreichung unlöslicher arzneistoffe
WO2004066361A3 (en) Monodisperse core/shell and other complex structured nanocrystals and methods of preparing the same
GB2395734A (en) Method of expanding a tubular element in a wellbore
MXPA03005496A (es) Metodo para preparar suspensiones de submicroparticulas.
ATE438432T1 (de) Schneideballon und verfahren
AR060234A1 (es) Gel de suspension espumable
AR022974A1 (es) Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble.
MXPA04003754A (es) Metodo de perforacion de pozos y fluido de perforacion.
WO2004037225A3 (en) Cosmetic and pharmaceutical foam
ATE273323T1 (de) INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
PE44799A1 (es) Antagonistas del receptor de vitronectina
WO2005038948A3 (en) Nanosized silver oxide powder
CA2541870A1 (en) Methods of fracturing a subterranean formation using a ph dependent foamed fracturing fluid
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
DE60224278D1 (de) Implantat, beispielsweise zahnimplantat
ES2187145T3 (es) Metodo de produccion de ligeles sustancialmente esfericos en agentes ililantes insolubles en agua.
AR009330A1 (es) Una composicion acuosa que contiene un vehiculo de hidrogel, su uso y un procedimiento para prepararla
DE602004014124D1 (de) Verfahren zur dispersion von wasserlöslichen oder hydrophilen substanzen in einem unter überkritischem druck stehenden fluid
PE20010712A1 (es) Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
SE0201289D0 (sv) Manufacture of polysaccharide beads
PT1151360E (pt) Processo de realizacao que utiliza um sistema de posicionamento global
PT1263413E (pt) Metodo de preparacao de dispersoes solidas